REDWOOD CITY, CA -- (Marketwire) -- 02/23/10 -- Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the fourth quarter and full year ended December 31, 2009. "In our first full year as an independent company, we made significant progress on each of our strategic objectives by advancing key pipeline programs into later ... read more

REDWOOD CITY, CA -- (Marketwire) -- 01/11/10 -- Facet Biotech Corporation (NASDAQ: FACT) today announced enrollment of the first patient into the randomized phase 2 portion of the ongoing Phase 1/2 study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM) in combination with lenalidomide and ... read more

REDWOOD CITY, CA -- (Marketwire) -- 12/10/09 -- Facet Biotech Corporation (NASDAQ: FACT) announced today that its board of directors has unanimously recommended that its stockholders not tender their shares into, and reject the unsolicited, revised, conditional tender offer from Biogen Idec Inc. (NASDAQ: BIIB) to acquire all of the outstanding shares of ... read more

REDWOOD CITY, CA -- (Marketwire) -- 12/08/09 -- Facet Biotech Corporation (NASDAQ: FACT) announced today its presentation of data regarding the company's proprietary next-generation protein engineering capabilities, including its PxP engineering technology, and identification of multiple novel optimized variants of four commercial antibodies: bevacizumab (Avastin®), cetuximab (Erbitux®), adalimumab (Humira®) and omalizumab (Xolair®). The data were ... read more

REDWOOD CITY, CA -- (Marketwire) -- 12/03/09 -- The board of directors of Facet Biotech Corporation (NASDAQ: FACT) today recommended that Facet Biotech's stockholders take no action at this time in response to the announcement by Biogen Idec Inc. (NASDAQ: BIIB) that it has revised its unsolicited conditional tender offer to acquire all ... read more

REDWOOD CITY, CA -- (Marketwire) -- 11/19/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that data for the company's elotuzumab and TRU-016 development programs will be presented at the American Society of Hematology (ASH) 2009 Annual Meeting and Exposition taking place in New Orleans, La. at the Ernest N. Morial Convention Center, ... read more

REDWOOD CITY, CA -- (Marketwire) -- 11/03/09 -- Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the third quarter ended September 30, 2009. "We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech. "We expect ... read more

REDWOOD CITY, CA -- (Marketwire) -- 10/28/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that it will release its financial results for the third quarter 2009 following the close of the U.S. financial markets on Tuesday, November 3, 2009. Following the release, Facet will hold a conference call at 4:30 p.m., Eastern ... read more

REDWOOD CITY, CA -- (Marketwire) -- 10/19/09 -- Facet Biotech Corporation (NASDAQ: FACT) today responded to Biogen Idec Inc.'s (NASDAQ: BIIB) announcement that it is extending its unsolicited tender offer to acquire all of the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. Faheem Hasnain, president and chief ... read more

REDWOOD CITY, CA -- (Marketwire) -- 09/09/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced the election of Hoyoung Huh, M.D, Ph.D. as a member of its board of directors effective September 5, 2009. "We are pleased to have Hoyoung, a biotechnology industry leader with extensive executive leadership, operating and business development experience, join ... read more

REDWOOD CITY, CA -- (Marketwire) -- 09/08/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that its board of directors has reviewed Biogen Idec Inc.'s unsolicited proposal with the assistance of its financial and legal advisors, Centerview Partners LLC and Simpson Thacher & Bartlett LLP, respectively, and determined that the $14.50 per share ... read more

REDWOOD CITY, CA -- (Marketwire) -- 09/04/09 -- Facet Biotech Corporation (NASDAQ: FACT) confirms that it is in receipt of Biogen Idec Inc.'s (NASDAQ: BIIB) letter dated September 4, 2009 offering $14.50 per share for all of the outstanding shares of Facet. Facet's board of directors, in consultation with its financial and legal advisors, ... read more

REDWOOD CITY, CA -- (Marketwire) -- 09/02/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that the company will participate at upcoming investor conferences. These conferences include: -- The Thomas Weisel Partners Healthcare Conference in Boston on Thursday, September 10, 2009 at 4:25 p.m., Eastern Time. -- The ... read more

REDWOOD CITY, CA -- (Marketwire) -- 08/04/09 -- Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the second quarter ended June 30, 2009. "I am pleased with the progress we've made at Facet over the past eight months, especially with our clinical development, where our daclizumab program in MS is poised to ... read more

REDWOOD CITY, CA -- (Marketwire) -- 07/30/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that the company will participate at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York on Wednesday, August 5, 2009 at 8:30 a.m., Eastern Time. A live webcast of the presentation and the ... read more

REDWOOD CITY, CA -- (Marketwire) -- 07/28/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that it will release its financial results for the second quarter 2009 following the close of the U.S. financial markets on Tuesday, August 4, 2009. Following the release, Facet will hold a conference call at 4:30 p.m. ... read more

REDWOOD CITY, CA -- (Marketwire) -- 07/09/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced the appointment of Mark Rolfe, Ph.D., as Senior Vice President and Chief Scientific Officer. Dr. Rolfe will be responsible for leading the company's research efforts, including target validation, translational medicine and protein engineering technologies. He will ... read more

REDWOOD CITY, CA -- (Marketwire) -- 05/13/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that the company will participate at the upcoming JMP Securities Research Conference in San Francisco on Tuesday, May 19, 2009 at 10:30 a.m. Pacific Time. A live webcast of the presentation and the Q&A session will be available through ... read more

REDWOOD CITY, CA -- (Marketwire) -- 05/07/09 -- Facet Biotech Corporation (NASDAQ: FACT) today announced that the company will participate at the upcoming Bank of America and Merrill Lynch 2009 Health Care Conference in New York City on Wednesday, May 13, 2009, at 9:20 a.m., Eastern Time. A live webcast of the presentation ... read more

REDWOOD CITY, CA -- (Marketwire) -- 05/05/09 -- Facet Biotech Corporation (NASDAQ: FACT) today reported financial results for the first quarter ended March 31, 2009. Summary of Financial Results The financial results for the quarter ended March 31, 2009 represent the first full quarter of operations for Facet as an independent company since its spin-off ... read more